A recent clinical trial showed that a PEA-based product was able to significantly reduce IBS symptoms in patients who did not respond to standard therapy
In addition, the population is expanding quickly, health and safety awareness is increasing, and tailored affinity bioprocess resin is still being developed
Gallbladder inflammation was reported less commonly, generally below 1%
It means the peptide is well-tolerated, does not produce meaningful adverse effects, and carries minimal risk for most users
Significant degradation has likely occurred over 8 to 12 hours at room temperature
Meanwhile, retatrutides early-stage data suggest even greater weight-loss potential, indicating a pipeline that could further reshape molecule-level rankings within the GLP-1 agonists market